The stress-induced chaperone protein Hsp70 enables the initiation and progression of many cancers, making it an appealing therapeutic target for development. Here we show that cancer cells resistant to Hsp70 inhibitors in vitro remain sensitive to them in vivo, revealing the pathogenic significance of Hsp70 in tumor stromal cells rather than tumor cells as widely presumed. Using transgenic mouse models of cancer, we found that expression of Hsp70 in host stromal cells was essential to support tumor growth. Furthermore, genetic ablation or pharmacological inhibition of Hsp70 suppressed tumor infiltration by macrophages needed to enable tumor growth. Overall, our results illustrate how Hsp70 inhibitors mediate the anti-cancer effects by targeting both tumor cells and tumor stromal cells, with implications for the broad use of these inhibitors as tools to ablate tumor-associated macrophages that enable malignant progression.
Introduction
Levels of the heat shock protein Hsp70 (HspA1A) have been implicated in cancer (1) (2) (3) (4) (5) . Genetic ablation of Hsp70 facilitated oncogene-induced senescence in Her2-positive breast cancer (6), (7) , (3) , which defines effects of Hsp70 on cancer initiation. Using PyMT model of breast cancer it was demonstrated that Hsp70 also has profound effects on metastasis (8) . The requirements for Hsp70 for cancer, prompted development of this protein as a drug target, and a number of Hsp70 inhibitors have been developed (see ref (2) for review).
Since micro-environment is emerging as a critical factor in tumor initiation and progression (9) , (10) , it is possible that Hsp70 expression in stroma may also be important for cancer development. For example, cancer-associated fibroblasts (CAF) can facilitate invasion and metastasis (9) , and the importance of CAF for tumor development was linked to heat shock transcription factor Hsf1 (11) . Tumor Associated Macrophages (TAM) can also supply cancer with EGF and angiogenic factors (12) , (13) , thus promoting invasion and metastasis (14) , (12, 15) .
Given a critical role of stroma in cancer, several drugs have been developed which target tumor microenvironment (10, 16) , but our options to target CAF or TAM are still limited. Here we demonstrate that stromal Hsp70 is critical for tumor development and that stromal macrophages can be effectively targeted by our Hsp70 inhibitor series. Macrophages migration assays: A. "Wound healing" assay: Macrophages were seeded on a 6-well plate (0.25x10 6 cells/well), and 5 d later cell monolayer was scratched using p200 tip.
Cells were treated with JG-98 or left untreated, and "wound healing" was recorded 24 h later.
For quantification, pictures were taken of three random fields along the scratch, and identical rectangles with width corresponding to the width of original scratch were drawn in these fields.
Cells migrated into the areas of these rectangles were counted, and data were normalized to the number of cells migrated in control scratch without JG-98 treatment. than HeLa (Fig. 1A) . On the other hand, when sensitivity to JG-98 was measured in vivo in xenograft models, tumors derived from HeLa cells were more resistant and tumors derived from MCF7 cells (Fig. 1B,C) . These sensitivity differences in vitro and in vivo suggested that tumor stroma may significantly contribute to the anti-tumor effect of JG-98.
To dissect the role of stroma in tumor sensitivity to JG-98, we sought to establish cancer cells (18), and FOXM1 (19) (Fig. 2C and S2 ). In addition, gene set enrichment analysis has identified that the RHO signaling pathway was also suppressed (Fig.   2D ). Among 36 components of the pathway, 15 were significantly downregulated (Table   S1 ).Therefore, inhibition of Hsp70 affects multiple pathways implicated in migration of macrophages, and ability of the latter to infiltrate tumors might be defined by cumulative defects in these pathways.
To evaluate effects of Hsp70 inhibition, macrophages were treated with JG-98, and their migration was assessed by "would healing" and transwell assays. In both assays JG-98 significantly suppressed macrophage migration (Figs. 2E) . Importantly, effects on migration were seen even at 300 nM concentration while toxicity was observed only at concentrations 3 μM (Fig. 2E) . Therefore, inhibition of Hsp70 has a profound effect on migration of macrophages and their infiltration into tumors. Since these mice are not immune compromised, we had to utilize mouse cancer cells compatible with this strain, e.g. B16 melanoma cells. Cells, developed visible tumors in almost 100% of WT animals within 6-8 days (Table 1) . However, when injected in Hsp70KO mice, these same cells did not produce tumors within at least 2 months (the period of observation) (Table 1) much lower number of macrophages migrated into the cancer cell mass in the Hsp70KO (Fig.   3A) . Therefore, Hsp70KO impairs macrophage infiltration, similar to JG-98 treatment. Notably, unlike in WT animals, there was a rim of macrophages surrounding tumors in Hsp70KO (Fig. S3) indicating that Hsp70KO affects macrophage infiltration into the tumor rather than macrophage number.
Knockout of
Following experiments with JG-98, we evaluated effects of the genetic ablation of Hsp70 on in vitro migration of macrophages isolated from WT and Hsp70KO mice. The knockout led to a significant suppression of macrophage migration in in vitro wound healing and transwell assays 
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